HC Wainwright began coverage on shares of Ovid Therapeutics (NASDAQ:OVID – Free Report) in a research note issued to investors on Monday, MarketBeat reports. The firm issued a buy rating and a $9.00 price target on the stock. HC Wainwright also issued estimates for Ovid Therapeutics’ Q1 2024 earnings at ($0.22) EPS, Q2 2024 earnings […]